Literature DB >> 21280004

Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus.

Jia Li1, Qiong Fu, Huijuan Cui, Bo Qu, Wen Pan, Nan Shen, Chunde Bao.   

Abstract

OBJECTIVE: An increased risk of premature atherosclerosis has been associated with systemic lupus erythematosus (SLE), and type I interferon (IFN) has been shown to play a pathogenic role in human SLE. The aim of this study was to determine whether IFNα is involved in the development of atherosclerosis in patients with SLE by promoting lipid uptake and macrophage-derived foam cell formation, which is a crucial step in early atherosclerosis.
METHODS: The effects of IFNα on lipid uptake and foam cell formation were determined by flow cytometry and oil red O staining. Messenger RNA and protein expression of scavenger receptors (SRs) was examined. Promoter activity was detected by luciferase reporter assay. Expression of macrophage SR class A (SR-A) and IFN-inducible genes (IFIGs) was measured in peripheral blood mononuclear cells obtained from 42 patients with SLE and 42 healthy donors.
RESULTS: IFNα priming increased the uptake of oxidized low-density lipoprotein and hence enhanced foam cell formation by up-regulating SR-A expression. IFNα increased SR-A expression via enhancing its promoter activities. Examination using signaling inhibitors revealed that a phosphatidylinositol 3-kinase/Akt signaling pathway appeared to be involved in this process. Notably, SR-A messenger RNA was significantly increased in patients with SLE compared to normal subjects and positively correlated with IFIG expression.
CONCLUSION: Our data suggest that IFNα priming up-regulated the expression of SR-A in human monocyte/macrophages, leading to increased lipid uptake and foam cell formation. Activation of the IFN signaling pathway may be linked to the risk of atherosclerosis by affecting plaque formation in patients with SLE. These findings provide novel insights into the mechanisms of and potential therapeutic approaches to premature atherosclerosis in patients with SLE.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21280004     DOI: 10.1002/art.30165

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  49 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

2.  Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Authors:  Ashley J Wilhelm; Amy S Major
Journal:  Int J Clin Rheumtol       Date:  2012-10-01

Review 3.  Type I interferon in the pathogenesis of lupus.

Authors:  Mary K Crow
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

4.  Oxidized LDL activated eosinophil polarize macrophage phenotype from M2 to M1 through activation of CD36 scavenger receptor.

Authors:  Minghui Qin; Lai Wang; Fuqiang Li; Mingjie Yang; Lei Song; Fang Tian; Ada Yukht; Prediman K Shah; Marc E Rothenberg; Behrooz G Sharifi
Journal:  Atherosclerosis       Date:  2017-05-20       Impact factor: 5.162

Review 5.  Inflammation-induced foam cell formation in chronic inflammatory disease.

Authors:  Thomas A Angelovich; Anna C Hearps; Anthony Jaworowski
Journal:  Immunol Cell Biol       Date:  2015-03-10       Impact factor: 5.126

Review 6.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 7.  Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

8.  Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux.

Authors:  Iryna Voloshyna; Isaac Teboul; Michael J Littlefield; Nicolle M Siegart; George K Turi; Melissa J Fazzari; Steven E Carsons; Joshua DeLeon; Allison B Reiss
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-27

Review 9.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

10.  Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.

Authors:  Jason S Knight; Wei Luo; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Venkataraman Subramanian; Chiao Guo; Robert C Grenn; Paul R Thompson; Daniel T Eitzman; Mariana J Kaplan
Journal:  Circ Res       Date:  2014-01-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.